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Introduction {#sec001}
============

Differentiation of nucleated cells including malignant cells in various body fluid (BF) samples is an essential technique to determine the clinical treatment strategies. A positive effusion for malignant cells is an important indicator in the diagnosis of malignant lesions and staging \[[@pone.0190886.ref001]\]. Therefore, the examination of BF for the presence of malignant cells has been accepted as a routine laboratory procedure, not only for the detection of incidental malignancy, but also for the detection of metastasis of an unknown primary origin \[[@pone.0190886.ref001], [@pone.0190886.ref002]\]. Especially, cytological examinations with papanicolaou and immunohistochemical stainings performed in pathology laboratories are of paramount importance in the diagnosis of malignancy in BF samples \[[@pone.0190886.ref002]--[@pone.0190886.ref004]\]. However, the routine cytology results are not available in the same day when the samples are sent to the lab, which prevents physicians from making a quick diagnosis. Hence, it is expected that the screening of malignant cells by the hematological examinations enables a rapid report to physicians and might be useful as adjunct rapid diagnosis tests. For example, in the differential diagnosis of coma patients, rapid automated analysis of CSF samples can benefit physicians' quick decision making \[[@pone.0190886.ref005]\]. Prompt detection of malignant cells in body fluid samples including bloods may be useful for the diagnosis of disseminated intravascular coagulation \[[@pone.0190886.ref006]\].

Although manual microscopic examinations are most widely used in hematology laboratories, those are time consuming and results are sometimes hampered by inter-examiners' variability in their skill levels. To date, many scientists and industries have been attempting to develop automated analyzing systems, and several different algorithms of the automated hematology analyzers have been developed to count and differentiate nucleated cells in various BF samples such as synovial, cerebrospinal, pleural, ascitic and pericardial fluids \[[@pone.0190886.ref007]--[@pone.0190886.ref010]\]. However, detection of malignant cells in BF samples by the hematology analyzers is still challenging because cell size, shape and cytoplasmic density of malignant cells vary as well as malignant cells often stick each other and form cell clumps.

Recently, a new detection mode, called high-fluorescence body fluid (HF-BF) \[[@pone.0190886.ref008], [@pone.0190886.ref011]\], has been equipped to the automatic hematoanalyzer Sysmex XN series (Sysmex, Kobe, Japan) perusing to discriminate non-haematopoietic cells. However, the nonmalignant cells such as mesothelial cells or macrophages are counted as the HF-BF cells along with malignant cells, and current HF-BF based analysis still causes false-positive results frequently. Thus, further improvement of the HF-BF to realize more accurate detection of malignant cells by modification of its parameter setting are warranted.

In this study, we propose a new XN-BF gating algorithm to detect malignant cells by modification of the conventional HF-BF algorithm. Specifically, two gating parameters, Rule 1 and Rule 2, based on the WDF channel were combined with HF-BF: (1) Rule 1 detects signals from large cells and clumped cells of which the most cells are consisted of clustered malignant cells; and (2) Rule 2 detects middle sized mononuclear cells with less granules than neutrophils and similar fluorescence signal to monocytes of which the most cells are consisted of hematological malignant cells and solid tumor cells. This novel algorithm was tested using various BF samples with and without malignant cells, and was evaluated by comparing with the cytological diagnosis in pathology laboratory.

Materials and methods {#sec002}
=====================

Patient samples {#sec003}
---------------

Between August 2013 and July 2014, a total of 92 BF samples were sent from different departments to the clinical laboratory of Juntendo University Hospital (Tokyo, Japan). The samples included 18 cerebrospinal fluid (CSF), 68 pleural effusion (PE) and 6 ascitic fluids for routine diagnosis of malignancy. The samples were stored in K~2~-EDTA tubes or sterile recipients without anticoagulant and requested to be sent to the laboratory immediately after collection. After arrival, automated analysis, manual microscopic WBC count and preparation of slides for microscopic cell differentiation were completed in hematology laboratory within two hours. Cytological examinations were performed at the pathology laboratory for these 92 BF samples. The study protocol was approved by the institutional review board of Juntendo University Hospital. Since all samples were de-identified, providing written informed consents to each patient was waved by the committee.

Cell analyses by BF mode on the Sysmex XN hematology analyzer {#sec004}
-------------------------------------------------------------

The XN-series analyzers are fully automated hematology analyzers equipped with dedicated BF measurement modes. To count and differentiate nucleated cells in BF, the cell membranes are perforated with Lysercell WDF^TM^ (Sysmex, Kobe, Japan), then intracellular organelles and nucleic acids are stained with Fluorocell WDF^TM^ (Sysmex, Kobe, Japan) so that the fluorescence flow cytometric analyses can detect specific side scattered signals which are generated depending on the type and quantity of intracellular organelles and nucleic acids. After treatments with these buffers, leukocytes rarely aggregate, and platelets are usually lysed (data not shown). Very small residual platelet and fibrin aggregates are almost negligible to affect forward scatter signals.

All BF samples were first analyzed by the BF mode of the XN-1000 Sysmex hematology analyzer (XN-BF) according to the manufacture's protocol. If clots or fibrins were observed, they were manually removed. The XN-BF mode utilizes the WBC differential (WDF) channel that simultaneously generates four signals of each cell passing through the focused laser beam in Flowcell (i.e., detecting chamber): (1) forward scatter signals indicating the volume of the cell; (2) side scatter signals providing the information about intracellular structures and contents such as nucleus and granules; (3) fluorescence intensity signals indicating the amount of intracellular nucleic acids (i.e., DNA and RNA) presenting in the cell; and (4) the forward scatter width signals providing the "time of flight" implying the doublets or highly aggregated cells passing through. The combination of these four signals of each cell depicts "scattergram" with which cells are analyzed and categorized into subgroups by using software algorithms.

Fluorescence signals were utilized to differentiate WBC from the non-haematopoietic HF-BF cells showing higher fluorescence intensity than the cutoff value. HF-BF cells were not included in the WBC counts and the amounts of HF-BF cells were expressed as a ratio over the WBCs (HF-BF/100 WBCs, abbreviated as 'HF-BF%') or absolute cell counts (number of HF-BF/μL, abbreviated as 'HF-BF\#'). The total nucleated cell count (TNC) is the sum of the number of WBCs and HF-BF cells. Each type of WBCs was classified as following: neutrophils and eosinophils are counted as polymorphonuclear (PMN) cells; lymphocytes and monocytes are counted as mononuclear (MN) cells; and mesothelial cells, macrophages and malignant cells are counted as HF-BF cells.

Novel scattergram gating algorithm {#sec005}
----------------------------------

The analyzed signals of the XN-BF were exported as FCS dataset for plotting WDF channel dot plots, or scattergrams. The analyses were performed using Flowing Software (Centre for Biotechnology, University of Turku, Finland: <http://flowingsoftware.btk.fi/>) \[[@pone.0190886.ref012]\]. Two following gating algorithm based on the WDF channel were combined: (1) Rule 1 was designed to detect the aggregated cells expressing higher forward scatter width signal and higher fluorescence signals than WBCs (as indicated in Area 1, [Fig 1A](#pone.0190886.g001){ref-type="fig"}); (2) Rule 2 was designed to detect middle range of fluorescence signals between WBCs and HF-BF cells with lower forward scatter signal compared to macrophages. This can differentiate the isolated malignant cells with similar size but generating higher fluorescence signals compared to the normal mononuclear cells (as indicated in Area 2, [Fig 1B](#pone.0190886.g001){ref-type="fig"}). BF samples that meet, at least, one criterion were detected as malignant cells.

![Schematic illustration of the XN-BF gating algorithm.\
(A) Area 1 includes the aggregated cells due to the high forward scatter width signals that implies the long "time of flight" of the cells passing though the laser beam in the flow-cell. The HF-BF cells gated in Area 1 are considered as the Rule1 positive cells. The horizontal axis indicates forward scatter pulse width signal and the vertical axis shows forward scatter signal in the 2D scattergram. In the 3D scattergram, X-axis shows side scatter signal, Y-axis is forward scatter signal and Z-axis indicates forward scatter pulse width signal. (B) Area 2 includes the non-aggregated HF-BF cell showing relatively low fluorescent signal intensity, which are defined as the Rule 2 positive cells. The horizontal axis indicates forward scatter signal and the vertical axis shows side fluorescence signal in the 2D scattergram. In the 3D scattergram, X-axis indicates side scatter signal, Y-axis shows side fluorescence signal and Z-axis is forward scatter signal. The gating illustrated based on the plotting WDF channel dot plots.](pone.0190886.g001){#pone.0190886.g001}

Manual microscopic analyses {#sec006}
---------------------------

A hemocytometer (Fuchs-Rosenthal Rotterdam, Netherlands) was used for manual microscopic cell counting. For cell differentiation, cytospin slides were prepared by cytocentrifugation at 80 x g for 10 min. BF with high TNC (\>1000 cells/μL) were diluted with Phosphate Buffered Saline (PBS) to obtain a concentration of 500--1000 cells/μL. Slides were stained by May-Grunwald-Giemsa. All slides were microscopically examined and performed differential count for 200 cells by an experienced medical technologist who was educated in hematopathology and cytopathology and a senior clinical pathologist. BF collection and analyses were performed in compliance with the CLSI H56-A guideline \[[@pone.0190886.ref013]\]. Concurrent pathological examinations were performed with Papanecolou (PAP) stained slides, followed by immunocytochemistry at an in-house pathology laboratory. Malignant cells were defined as ≥ Class IIIb (Papanicolaou class system) by the cytological examination.

Statistics {#sec007}
----------

The accuracy to detect malignant cells among various methods were evaluated by Mann-Whitney U-test where appropriate. *p*\<0.05 was considered as statistically significant.

Results {#sec008}
=======

Comparison of the accuracy of the XN-BF analysis and the microscopic examinations in the hematology laboratory compared to the examinations in the cytology laboratory {#sec009}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------

[Table 1](#pone.0190886.t001){ref-type="table"} summarizes the results of automated analyses and manual microscopic examinations. In the 92 BF samples, malignant cells were detected in 27 samples by the cytology examination. Although these two new algorithms (i.e., Rule 1 and Rule 2) are supposed to work complementally, there are some difference in the accuracy in the detection of malignant cells. Of the 27 malignant samples, five samples were detected by Rule 1 and 2 (18.5%), nine samples were detected by Rule 1 alone (33.3%), three samples were detected by Rule 2 alone (7.40%) and nine samples were not detected as malignant by either method (33.3%).

10.1371/journal.pone.0190886.t001

###### Characteristics of BF samples.

![](pone.0190886.t001){#pone.0190886.t001g}

  Sample \#   Material                                  Pathology                                            XN-BF data   Malignancy                                 
  ----------- ----------------------------------------- ----------------------------------------- ---------- ------------ ------------ ------ ------- ---- ---- ---- ----
  1           PE[†](#t001fn001){ref-type="table-fn"}    Adenocarcinoma                            V          1828         998          830    83.2    \+   \+   \+   \+
  2           PE                                        Adenocarcinoma                            V          1241         771          470    61.0    \+   \+   \+   \+
  3           PE                                        Adenocarcinoma                            V          2460         1623         837    51.6    \+   \+   \-   \+
  4           PE                                        Adenocarcinoma                            V          3597         2526         1071   42.4    \+   \+   \+   \+
  5           PE                                        Adenocarcinoma                            V          3424         2723         701    25.7    \+   \+   \+   \+
  6           PE                                        Lung Adenocarcinoma                       V          1469         342          1127   329.5   \+   \-   \+   \+
  7           PE                                        Malignant Lymphoma                        V          1333         612          721    117.8   \+   \-   \+   \+
  8           PE                                        Adenocarcinoma                            V          1528         1018         510    50.1    \+   \-   \-   \+
  9           PE                                        Adenocarcinoma                            V          353          271          82     30.3    \+   \-   \+   \+
  10          AF[‡](#t001fn002){ref-type="table-fn"}    Adenocarcinoma                            V          124          100          24     24.0    \+   \-   \+   \+
  11          PE                                        Small cell carcinoma                      V          2124         1733         391    22.6    \+   \-   \+   \+
  12          AF                                        Adenocarcinoma                            V          1404         1160         244    21.0    \+   \-   \+   \+
  13          PE                                        Adenocarcinoma                            V          385          344          41     11.9    \+   \-   \+   \+
  14          PE                                        Lung Adenocarcinoma                       V          1391         1320         71     5.4     \+   \-   \+   \+
  15          PE                                        Adenocarcinoma                            V          218          124          94     75.8    \-   \+   \+   \+
  16          PE                                        Malignant Mesothelioma                    V          426          358          68     19.0    \-   \+   \+   \+
  17          PE                                        Adenocarcinoma                            V          609          494          115    23.3    \-   \-   \-   \-
  18          PE                                        Adenocarcinoma                            V          297          277          20     7.2     \-   \-   \+   \-
  19          PE                                        Adenocarcinoma                            IIIb       1682         1590         92     5.8     \-   \-   \-   \-
  20          PE                                        Adenocarcinoma                            V          2773         2647         126    4.8     \-   \-   \+   \+
  21          PE                                        Adenocarcinoma                            V          386          376          10     2.7     \-   \-   \-   \-
  22          PE                                        Lung Adenocarcinoma                       V          3888         3806         82     2.2     \-   \-   \+   \-
  23          PE                                        Malignant Lymphoma                        V          2927         2885         42     1.5     \-   \-   \-   \-
  24          PE                                        Adenocarcinoma                            V          3786         3737         49     1.3     \-   \-   \-   \-
  25          AF                                        Adenocarcinoma                            V          207          182          25     13.7    \-   \-   \-   \-
  26          CSF[§](#t001fn003){ref-type="table-fn"}   unknown                                   V          909          373          536    143.7   \-   \+   \+   \+
  27          CSF                                       Medullobrastoma                           V          53           50           3      6.0     \-   \-   \+   \-
  28          PE                                        N/D[¶](#t001fn004){ref-type="table-fn"}   Ⅱ          5692         4977         715    14.4    \+   \+   \+   \+
  29          PE                                        N/D                                       Ⅱ          5458         5240         218    4.2     \+   \-   \-   \-
  30          PE                                        N/D                                       Ⅱ          2785         2558         227    8.9     \+   \-   \-   \-
  31          PE                                        N/D                                       Ⅱ          1203         985          218    22.1    \-   \+   \+   \+
  32          PE                                        N/D                                       Ⅱb         2106         1825         281    15.4    \-   \+   \-   \-
  33          PE                                        N/D                                       Ⅱ          106          84           22     26.2    \-   \+   \-   \-
  34          PE                                        N/D                                       Ⅱ          217          193          24     12.4    \-   \+   \-   \-
  35          PE                                        N/D                                       Ⅱ          261          219          42     19.2    \-   \+   \-   \-
  36          PE                                        N/D                                       Ⅲ          89           85           4      4.7     \-   \-   \-   \+
  37          PE                                        N/D                                       Ⅱ          949          856          93     10.9    \-   \-   \-   \+
  38          PE                                        N/D                                       Ⅱ          3596         3500         96     2.7     \-   \-   \-   \+
  39          PE                                        N/D                                       Ⅲ          949          816          133    16.3    \-   \-   \-   \-
  40          PE                                        N/D                                       Ⅲ          48           45           3      6.7     \-   \-   \-   \-
  41          PE                                        N/D                                       Ⅲ          1008         994          14     1.4     \-   \-   \-   \-
  42          PE                                        N/D                                       Ⅲ          307          287          20     7.0     \-   \-   \-   \-
  43          PE                                        N/D                                       Ⅲ          242          219          23     10.5    \-   \-   \-   \-
  44          PE                                        N/D                                       Ⅲ          6760         6647         113    1.7     \-   \-   \-   \-
  45          PE                                        N/D                                       Ⅲ          7037         6668         369    5.5     \-   \-   \-   \-
  46          PE                                        N/D                                       Ⅱb         208          174          34     19.5    \-   \-   \-   \-
  47          PE                                        N/D                                       Ⅱb         1114         1031         83     8.1     \-   \-   \-   \-
  48          PE                                        N/D                                       Ⅱ          59           58           1      1.7     \-   \-   \-   \-
  49          PE                                        N/D                                       Ⅱ          36           34           2      5.9     \-   \-   \-   \-
  50          PE                                        N/D                                       Ⅱ          359          357          2      0.6     \-   \-   \-   \-
  51          PE                                        N/D                                       Ⅱ          609          606          3      0.5     \-   \-   \-   \-
  52          PE                                        N/D                                       Ⅱ          706          702          4      0.6     \-   \-   \-   \-
  53          PE                                        N/D                                       Ⅱ          1914         1907         7      0.4     \-   \-   \-   \-
  54          PE                                        N/D                                       Ⅱ          5216         5207         9      0.2     \-   \-   \-   \-
  55          PE                                        N/D                                       Ⅱ          193          173          20     11.6    \-   \-   \-   \-
  56          PE                                        N/D                                       Ⅱ          239          217          22     10.1    \-   \-   \-   \-
  57          PE                                        N/D                                       Ⅱ          842          817          25     3.1     \-   \-   \-   \-
  58          PE                                        N/D                                       Ⅱ          1753         1728         25     1.4     \-   \-   \-   \-
  59          PE                                        N/D                                       Ⅱ          208          178          30     16.9    \-   \-   \-   \-
  60          PE                                        N/D                                       Ⅱ          273          243          30     12.3    \-   \-   \-   \-
  61          PE                                        N/D                                       Ⅱ          6651         6620         31     0.5     \-   \-   \-   \-
  62          PE                                        N/D                                       Ⅱ          1014         972          42     4.3     \-   \-   \-   \-
  63          PE                                        N/D                                       Ⅱ          6632         6578         54     0.8     \-   \-   \-   \-
  64          PE                                        N/D                                       Ⅱ          509          452          57     12.6    \-   \-   \-   \-
  65          AF                                        N/D                                       Ⅱ          1271         1197         74     6.2     \-   \-   \-   \-
  66          PE                                        N/D                                       Ⅱ          777          699          78     11.2    \-   \-   \-   \-
  67          PE                                        N/D                                       Ⅱ          1945         1838         107    5.8     \-   \-   \-   \-
  68          PE                                        N/D                                       Ⅱ          2354         2234         120    5.4     \-   \-   \-   \-
  69          PE                                        N/D                                       Ⅱ          2232         2107         125    5.9     \-   \-   \-   \-
  70          AF                                        N/D                                       Ⅱ          548          399          149    37.3    \-   \-   \-   \-
  71          PE                                        N/D                                       Ⅱ          1736         1470         266    18.1    \-   \-   \-   \-
  72          PE                                        N/D                                       Ⅱ          3891         3539         352    9.9     \-   \-   \-   \-
  73          PE                                        N/D                                       Ⅱ          3148         2746         402    14.6    \-   \-   \-   \-
  74          AF                                        N/D                                       Ⅱ          268          253          15     5.9     \-   \-   \-   \-
  75          PE                                        N/D                                       Ⅱ          1166         1143         23     2.0     \-   \-   \-   \-
  76          PE                                        N/D                                       Ⅱ          1127         1096         31     2.8     \-   \-   \-   \-
  77          CSF                                       N/D                                       Ⅲ          2            2            0      0.0     \-   \-   \-   \-
  78          CSF                                       N/D                                       Ⅲ          8            8            0      0.0     \-   \-   \-   \-
  79          CSF                                       N/D                                       Ⅲ          112          106          6      5.7     \-   \-   \-   \-
  80          CSF                                       N/D                                       Negative   1            1            0      0.0     \-   \-   \-   \-
  81          CSF                                       N/D                                       Negative   1            1            0      0.0     \-   \-   \-   \-
  82          CSF                                       N/D                                       Negative   1            1            0      0.0     \-   \-   \-   \-
  83          CSF                                       N/D                                       Negative   2            2            0      0.0     \-   \-   \-   \-
  84          CSF                                       N/D                                       Negative   2            2            0      0.0     \-   \-   \-   \-
  85          CSF                                       N/D                                       Negative   2            2            0      0.0     \-   \-   \-   \-
  86          CSF                                       N/D                                       Negative   11           10           1      10.0    \-   \-   \-   \-
  87          CSF                                       N/D                                       Negative   7            7            0      0.0     \-   \-   \-   \-
  88          CSF                                       N/D                                       Negative   246          241          5      2.1     \-   \-   \-   \-
  89          CSF                                       N/D                                       Negative   115          115          0      0.0     \-   \-   \-   \-
  90          CSF                                       N/D                                       Negative   23           22           1      4.5     \-   \-   \-   \-
  91          CSF                                       N/D                                       Negative   5            5            0      0.0     \-   \-   \-   \-
  92          CSF                                       N/D                                       Negative   10           9            1      11.1    \-   \-   \-   \-

†PE, pleural effusion

‡AF, ascitic fluid

§CSF, cerebrospinal fluid

¶N/D, not detected

The accuracy of the XN-BF gating algorithm as well as the manual microscopic examinations in hematology laboratory in the detection of malignant cells were evaluated by a comparison with the cytological diagnosis. [Table 2](#pone.0190886.t002){ref-type="table"} summarized the results of accuracy by the three types of examinations performed in hematology laboratory showed high specificities (87.7--96.9%) but relatively low sensitivities (63.0--70.4%), with the highest accuracy of the WBC differential examination with May-Grunwald-Giemsa staining. We, then, analyzed the difference between true positive and false negative with the XN-BF gating algorithm in the cytology positive malignant BF samples. As shown in [Table 3](#pone.0190886.t003){ref-type="table"}, the false negative samples contained significantly lower number of HF-BF cells (*p* = 0.008) than the true positive samples, which indicates that a small malignant cells number is at least one of the causes of the false negative with the XN-BF gating algorithm. No significant difference was observed among these methods in total cell numbers or WBC numbers.

10.1371/journal.pone.0190886.t002

###### Performance of examinations in hematology laboratory in the detection of BF malignancy compared with cytological diagnosis.

![](pone.0190886.t002){#pone.0190886.t002g}

  Type of examination                                        Sensitivity (%)   Specificity (%)   Positive Predictive Value (%)   Negative Predictive Value (%)
  ---------------------------------------------------------- ----------------- ----------------- ------------------------------- -------------------------------
  XN-BF gating algorism                                      63.0              87.7              68.0                            85.1
  Microscopic WBC differential (May-Grunwald Giemsa stain)   70.4              96.9              90.5                            88.7
  Microscopic WBC count (Fuchs-Rosental)                     66.7              92.3              78.3                            87.0

10.1371/journal.pone.0190886.t003

###### Sysmex XN-BF data and performance of examinations in hematology laboratory to detect malignancy.

![](pone.0190886.t003){#pone.0190886.t003g}

  XN-BF data            XN-BF gating algorism   Microscopic WBC differential   Microscopic WBC count                                                       
  --------------------- ----------------------- ------------------------------ ----------------------- ------------ ------------ ------------ ------------ -------------
  Total cell \# (/μL)   1457 ± 265              1592 ± 448                                             1485 ± 281   1698 ± 455   1499 ± 248   1537 ± 530   
  WBC \# (/μL)          1001 ± 203              1492 ± 452                                             1108 ± 251   1488 ± 447   1058 ± 206   1489 ± 525   
  HF-BF \# (/μL)        455 ± 96                100 ± 45                       *p* = 0.008             377 ± 84     210 ± 106    441 ± 87     49 ± 13      *p* = 0.004
  HF-BF % (%)           61±19                   19 ± 13                                                54 ± 17      19 ± 7       62 ± 18      7 ± 2        *p* = 0.044

The data are presented as mean ± SEM.

The examples in the detection of malignant cells by the new algorithms {#sec010}
----------------------------------------------------------------------

As described in the methods, the XN-BF gating algorithm is supposed to detect malignant cells with relatively large size and/or cell clumps by Rule 1, and cells contains condensed intracellular contents such as RNAs and DNAs are supposed to be detected by Rule 2. [Fig 2](#pone.0190886.g002){ref-type="fig"} shows representative scattergrams of XN-BF and corresponding May-Grunwald-Giemsa staining photomicrographs. [Fig 2A](#pone.0190886.g002){ref-type="fig"} through C show representative body fluids with true positive results of the XN-BF gating algorithm. Malignant cells detected by Rule 1 and/or Rule 2. [Fig 2A](#pone.0190886.g002){ref-type="fig"} shows a malignant PE (sample \#4, [Table 1](#pone.0190886.t001){ref-type="table"}) detected as malignancy by the XN-BF gating algorithm (positive by both Rule 1 and 2) containing highly aggregated adenocarcinoma cells (88.7% by microscopic differential count). [Fig 2B](#pone.0190886.g002){ref-type="fig"} shows a malignant PE (sample \#13, [Table 1](#pone.0190886.t001){ref-type="table"}) detected as malignancy (Rule 1 positive, but Rule 2 negative) with the isolated cluster of adenocarcinoma cells (11.8% by the microscopic differential count). [Fig 2C](#pone.0190886.g002){ref-type="fig"} is a malignant mesothelioma PE (sample \#16, [Table 1](#pone.0190886.t001){ref-type="table"}) detected as malignancy (Rule 1 negative, but Rule 2 positive) containing malignant cells with isolated and sparse form (7.6% by the microscopic differential count). [Fig 2D](#pone.0190886.g002){ref-type="fig"} shows a malignant PE (sample \#18, [Table 1](#pone.0190886.t001){ref-type="table"}) interpreted as negative for malignancy by the XN-BF gating algorithm (negative by both Rule 1 and 2) containing small number of isolated adenocarcinoma cells (1.5% by the microscopic differential count).

![Representative analyses of body fluid samples by the XN-BF gating algorithm and photomicrographs of their corresponding cytospins.\
Representative XN-BF scattergrams (Rule1 and Rule2) and pictures of cytospin slides of the exact same samples (May-Grunwald-Giemsa, original magnification x10 and x50). (A) PE with adenocarcinoma cells (sample \#4, [Table 2](#pone.0190886.t002){ref-type="table"}). Rule 1 positive and Rule 2 positive by the XN-BF gating algorithm. (B) PE with adenocarcinoma cells (sample \#13, [Table 2](#pone.0190886.t002){ref-type="table"}). Rule 1 positive, but Rule 2 negative by the XN-BF gating algorithm. (C) PE with malignant mesothelioma cells (sample \#16, [Table 2](#pone.0190886.t002){ref-type="table"}) Rule 1 negative, but Rule 2 positive by the XN-BF gating algorithm. **(**D) PE with adenocarcinoma cells (sample \#18, [Table 2](#pone.0190886.t002){ref-type="table"}) interpreted as negative for malignancy by the XN-BF gating algorithm (Rule 1 negative and Rule 2 negative).](pone.0190886.g002){#pone.0190886.g002}

Discussion {#sec011}
==========

In this study, we investigated the accuracy of a newly developed XN-BF gating algorithm in the detection of malignant cells using Sysmex XN-1000 automated hematology analyzer. As described in the method section, this algorithm was designed to detect malignant cells by addition of two detection rules to the conventional Sysmex XN-BF mode: (1) measuring passing time that is affected by cell clumps; and (2) measuring fluorescence intensity reflected by cytoplasmic organelles and nucleus contents. Whereas the sophisticated algorithms are developed for automatic computational algorithms of flowcytometry \[[@pone.0190886.ref014]\], our gating analyses were performed manually and our system is not using various CD markers or other special staining. This study is attempting to develop a relatively simple and more accurate detection system compared to the conventional manual microscopic examination that performed by simple May-Grunwald-Giemsa staining in hematology laboratories rather than full cytology examination in pathology laboratories at stage.

We and others have reported the difficulties to distinguish malignant cells from benign ones containing macrophages and mesothelial cells by the conventional Sysmex HF-BF mode because of its low specificity \[[@pone.0190886.ref008], [@pone.0190886.ref013]\]. This is mainly due to the use of only two detection algorithms: (1) forward scattering signal detection that can evaluate size of cells; and (2) side scattering signal detection algorithm that can detect the reflection of laser beams by cyto organells. Recently, Labaere et al. analyzed BF samples by HF-BF mode of Sysmex XN-2000 with a cut off level of ≥17 HF-BF cells /μL to detect malignant cells, and reported still relatively low specificity of 61% compared to the conventional microscopic examination with May-Grunwarld Giemsa stained slides performed in hematology laboratory \[[@pone.0190886.ref008]\]. Malignant cells show several unique features compared to normal blood cells: (1) these cells are usually larger than normal hematocytes; (2) these cells contain more DNAs and RNAs than normal hematocytes \[[@pone.0190886.ref015]\]; (3) these cells' cytoorganelles are often more complicated than non-malignant cells; and (4) these cells have tendency to form cell clumps. We, therefore, developed a new algorithm by addition of two parameters, Rule 1 and Rule 2, to detect malignant cells more specifically, and achieved markedly high specificity of 87.8% compared to the conventional microscopic differential count with May-Grunwarld Giemsa stain in hematology laboratory. This means that the XN-BF gating algorithm reduces unnecessary microscopic analyses. On the other hands, we observed false negative results in the cases with small number of malignant cells. Further studies using more samples obtained from various kinds of body fluid samples are warranted to validate our current estimation. We are planning to expand our study to incorporate data from multiple centers, and adding more developed technology such as automated digital morphological analyzer, DI-60 which is equipped with Sysmex XN series. The combinational usage of automated high definition microscopy images may improve both specificity and sensitivity. The number of similar studies using XN-series automated analyzers is rapidly increasing all over the world. Since 2012, more than 100 studies using the XN-series have been published (referred in PubMed), and the number of studies is increasing year-by-year. To date, more than 20,000 XN-series hematology analyzers were shipped to all over the world including approximately 5000 of XN analyzers to the U.S. Thus, we believe that the XN-series analyzers have been used in many laboratories as automated hematology analyzer.

In this study, we observed that the tested different hematological examinations, including the XN-BF gating algorithm and the manual microscopic examinations in hematology laboratory, showed similar sensitivity and specificity compared to the cytological examinations. Whereas the accuracy of the XN-BF gating mode needs to be improved to attain higher sensitivity, this system might facilitate a feature upgrade of the automated hematology analyzer to detect malignant cells in BF.

As the study limitations, this is a single center study with relatively small size samples. The number of samples and type of malignant cells for each type of BF were limited. Although we examined cells from same samples for automated analyses and microscopic examinations in hematology laboratory, it was not possible to analyze exact the same cells for cytopathology laboratory since it is not feasible to collect a single cell from flow cytometry to fix and stain for cytopathological examinations. In addition, microscopic examinations by interexaminers' and/or intraexaminers' inconsistency could not be completely removed even though two well-trained examiners performed the studies. These issues cannot be avoided in any laboratories, and we are increasing number of samples for each kind of BF for the future study.

In conclusion, the XN-BF gating algorithm for the BF malignancy diagnosis may have a potential to be the alternative method to the morphological examination, which can benefit for hematology laboratories to screen malignant cells rapidly without requiring additional sample preparation procedure and with minimal operator bias. Currently, manual microscopic examination is the golden standard. However, in the future, we believe that accuracy and quality of automated analyses of BF samples can be further improved with the technology development, and that this type of automated detecting system can serve as an adjunct quality control system.
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